Internal Medicine, Rheumatology · Orange, CA
NPI
1154306678
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
805 W la Veta Ave, Suite 105
Orange, CA, 92868
Phone (714) 628-9342
Groups this clinician bills Medicare through
Medicare paid, 2024
$197K
5,365 services
Medicare patients, 2024
365
Average age 74
Drug cost, 2024
$3.0M
2,724 prescriptions
Company payments, 2025
$4,374
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Behnam Khaleghi was code J1010 (injection, methylprednisolone acetate, 1 mg), 1,100 times for 22 patients. In total Behnam Khaleghi billed 5,365 services in 30 codes, and Medicare paid $197K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-02-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,100 | 22 | $0.10 | $113 |
| 99215 Office E&M - Established | Office | 349 | 184 | $145.18 | $51K |
| 99214 Office E&M - Established | Office | 296 | 170 | $103.28 | $31K |
| 20611 Joint Injection | Office | 165 | 40 | $87.12 | $14K |
| 99213 Office E&M - Established | Office | 145 | 47 | $78.67 | $11K |
| J7321 Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | Office | 109 | 27 | $57.29 | $6,244 |
| 76882 Ultrasound - Nonspecific | Office | 97 | 56 | $55.75 | $5,408 |
| 99204 Office E&M - New | Office | 70 | 70 | $137.98 | $9,659 |
| 96372 Injection Administration | Office | 65 | 37 | $12.29 | $799 |
| 99205 Office E&M - New | Office | 60 | 60 | $170.17 | $10K |
| 96365 Intravenous Infusion, Hydration | Office | 37 | 22 | $55.35 | $2,048 |
| 96413 Chemotherapy Administration | Office | 15 | 11 | $119.18 | $1,788 |
| 99203 Office E&M - New | Office | 11 | 11 | $96.75 | $1,064 |
By year: 2022 $118K for 1,380 services; 2023 $133K for 1,666 services; 2024 $197K for 5,365 services.
Medicare prescription drug claims, 2024
In 2024, the drug Behnam Khaleghi prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 334 prescriptions and refills. In total Behnam Khaleghi wrote 2,724 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 334 | 726 | 93 | $8,346 |
| Prednisone Generic | 289 | 451 | 110 | $1,610 |
| Hydroxychloroquine Sulfate Generic | 246 | 525 | 87 | $9,363 |
| Gabapentin Generic | 202 | 364 | 79 | $1,690 |
| Duloxetine Hcl Generic | 186 | 308 | 71 | $3,283 |
| Leflunomide Generic | 107 | 249 | 48 | $6,669 |
| Prolia Denosumab | 97 | 577 | 59 | $158K |
| Folic Acid Generic | 73 | 184 | 31 | $544 |
| Diclofenac Sodium Generic | 72 | 86 | 38 | $1,671 |
| Humira(Cf) Pen Adalimumab | 69 | 84 | Under 11 | $606K |
| Sulfasalazine Generic | 59 | 125 | 26 | $1,427 |
| Alendronate Sodium Generic | 43 | 87 | 18 | $375 |
| Pregabalin Generic | 42 | 48 | 19 | $937 |
| Enbrel Sureclick Etanercept | 42 | 46 | Under 11 | $339K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 39 | 39 | 27 | $911 |
Brand drugs: 581 claims; generic drugs: 2,132 claims; opioid claims: 105.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Behnam Khaleghi $4,374 ($4,374 in general payments such as food, travel and fees) from 22 companies. The largest payer was Abbvie Inc. with $711.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 29 | $711 |
| Amgen Inc. AMGN | 29 | $591 |
| Novartis Pharmaceuticals Corporation NVS | 24 | $527 |
| GlaxoSmithKline, LLC. GSK | 16 | $437 |
| Lilly USA, LLC LLY | 19 | $394 |
| Janssen Biotech, Inc. JNJ | 14 | $365 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $283 |
| Pfizer Inc. PFE | 11 | $199 |
| Radius Health, Inc. | 6 | $196 |
| UCB, Inc. UCB.BR | 8 | $192 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.